ClinicalTrials.gg
Drug

Serplulimab clinical trials

Also written HLX10.

studies test it
107
open now
69
in phase 3
16
first study started
2018

How each study uses serplulimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the serplulimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
3 Feb 2025 · Hetronifly · EMEA/H/C/006170 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Serplulimab
54
Carboplatin
3
Recombinant humanized anti-PD-1 monoclonal antibody injection
3
Oxaliplatin
2
etoposide
2

Development codes

HLX10
26
HLX-10LX
1

In one entry with another drug

Given together, or one or the other

Serplulimab + Fruquintinib
2

Studies by the year they started

107 studies that test it; most in 2023 (29)

Studies that test serplulimab, by start year
YearStudies
20182
20197
20202
20212
202213
202329
202416
202514
202622

Who runs them

Industry 26 · Other 81

Shanghai Henlius Biotech (24) · Fudan University (9) · Sun Yat-sen University (5) · Tianjin Medical University Cancer Institute and Hospital (5) · RenJi Hospital (4) · Henan Cancer Hospital (4) · Fujian Cancer Hospital (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3)

Often tested with

Tested in the same studies.

Bevacizumab (7) · HMPL-013 (6) · HLX07 (5) · HLX04 (4) · CAPOX Regimen (4) · Paclitaxel (4) · Carboplatin (4) · Etoposide (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 22, 2 in phase 3

Studies that test serplulimab, phase 3 first.

Studies

Open first, then newest update. How each study uses serplulimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 107

See all 107 studies that test serplulimab →

Given beside what is tested · 38 — serplulimab is usual care or a partner of the new treatment

Showing 20 of 38.

Codes

What other systems call serplulimab · ClinicalTrials.gg INT002208

  • MeSH (NLM) C000732065serplulimabOne source NLM
  • UNII (FDA) S3GQZ2K36VSERPLULIMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q130351954serplulimabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C156738SerplulimabOne source FDA
  • DrugBank DB17451One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.